This site is intended for healthcare professionals

FDA accepts Alkermes' resubmission of NDA for ALKS 3831 to treat adults with schizophrenia and adults with bipolar I disorder.

Read time: 1 mins
Last updated:28th Jun 2021
Published:30th Dec 2020
Condition: Schizophrenia + Bipolar Disorder
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest